Exploring the Effects of Corticosteroids on the Human Hippocampus using Neurocognitive Testing and High-Resolution Brain Imaging

使用神经认知测试和高分辨率脑成像探索皮质类固醇对人类海马的影响

基本信息

  • 批准号:
    10556437
  • 负责人:
  • 金额:
    $ 72.79万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2019
  • 资助国家:
    美国
  • 起止时间:
    2019-04-01 至 2025-01-31
  • 项目状态:
    未结题

项目摘要

Abstract Chronic corticosteroid (CS) exposure is associated with changes in memory and the hippocampus in both humans and in animal models. The hippocampus has a high concentration of glucocorticoid receptors (GCRs), and the pre-clinical literature demonstrates shortening of apical dendrites in the CA3 region of the hippocampus and decreased neurogenesis in the dentate gyrus (DG) following CS administration. In humans, both stress and CS exposure are associated with a decline in declarative memory performance (a process mediated by the hippocampus). Impairment in declarative memory and hippocampal atrophy are reported in patients with excessive CS release due to Cushing's disease, and, by our group, in patients receiving prescription CS therapy. These findings have important implications for patients with mood disorders, as a large subset of people with major depressive disorder (MDD) show evidence of HPA axis activation, elevated cortisol and, importantly, resistance to the effects of CSs on both the HPA axis and on declarative memory. Thus, resistance to corticosteroids appears to be a consequence of MDD. Our prior work has shown memory deficits in persons receiving prescription CSs (e.g., prednisone) or healthy controls briefly administered hydrocortisone (cortisol). Our pilot data suggest that 3-day administration of hydrocortisone is associated with reversible decline in declarative memory, decrease in task-related hippocampal activation, and a significant, but reversible, decrease in hippocampal volume. Decrease in hippocampal volume was greater in women and correlated with increases in serum cortisol levels. Based on these data, we propose to examine changes in declarative memory, as well as use state-of-the-art high- resolution multimodal neuroimaging, including structural and functional (i.e., task-based and resting state) MRI, in both men and women healthy controls, and, as an exploratory aim, a depressed group, given 3-day exposures to hydrocortisone (160 mg/day) or placebo. The study will translate preclinical findings to humans, provide valuable data on possible sex differences in the response to cortisol and, for the first time, identify specific hippocampal subfields (e.g., CA3/DG) in humans that are most sensitive to acute CS effects. Using resting state fMRI data and whole brain connectomics using graph theoretical approaches, we will determine the effects of cortisol exposure on functional brain networks. Furthermore, this will be the first study to use neuroimaging to compare the brain's response to CSs in people with depression vs. controls, and determine whether depressed people demonstrate glucocorticoid resistance within the hippocampus. We hypothesize that hippocampal response to acute CSs will be greatest in the CA3/DG subfield, greater in women than in men, and that depressed people will show a blunted hippocampal response to CSs compared to controls. A multidisciplinary research team with extensive experience in CS effects on the brain and hippocampal subfield neuroimaging, and a prior history of research collaboration, will conduct the project.
摘要

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

E SHERWOOD BROWN其他文献

E SHERWOOD BROWN的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('E SHERWOOD BROWN', 18)}}的其他基金

T35 NIAAA Summer Research Program
T35 NIAAA 夏季研究计划
  • 批准号:
    10627715
  • 财政年份:
    2023
  • 资助金额:
    $ 72.79万
  • 项目类别:
Exploring the Effects of Corticosteroids on the Human Hippocampus using Neurocognitive Testing and High-Resolution Brain Imaging
使用神经认知测试和高分辨率脑成像探索皮质类固醇对人类海马的影响
  • 批准号:
    10333336
  • 财政年份:
    2019
  • 资助金额:
    $ 72.79万
  • 项目类别:
Exploring the Effects of Corticosteroids on the Human Hippocampus using Neurocognitive Testing and High-Resolution Brain Imaging
使用神经认知测试和高分辨率脑成像探索皮质类固醇对人类海马的影响
  • 批准号:
    10091987
  • 财政年份:
    2019
  • 资助金额:
    $ 72.79万
  • 项目类别:
Exploring the Effects of Corticosteroids on the Human Hippocampus using Neurocognitive Testing and High-Resolution Brain Imaging
使用神经认知测试和高分辨率脑成像探索皮质类固醇对人类海马的影响
  • 批准号:
    9898466
  • 财政年份:
    2019
  • 资助金额:
    $ 72.79万
  • 项目类别:
A Neurosteroid Intervention for Menopausal and Perimenopausal Depression
神经类固醇干预治疗更年期和围绝经期抑郁症
  • 批准号:
    10359033
  • 财政年份:
    2018
  • 资助金额:
    $ 72.79万
  • 项目类别:
The Dallas Asthma Brain and Cognition Study (Dallas ABC Study)
达拉斯哮喘大脑和认知研究(达拉斯 ABC 研究)
  • 批准号:
    10219346
  • 财政年份:
    2018
  • 资助金额:
    $ 72.79万
  • 项目类别:
Dopamine-2 Receptor Partial Agonist for Bipolar Disorder and Alcohol Use Disorder
多巴胺 2 受体部分激动剂治疗双相情感障碍和酒精使用障碍
  • 批准号:
    9976319
  • 财政年份:
    2016
  • 资助金额:
    $ 72.79万
  • 项目类别:
Dopamine-2 Receptor Partial Agonist for Bipolar Disorder and Alcohol Use Disorder
多巴胺 2 受体部分激动剂治疗双相情感障碍和酒精使用障碍
  • 批准号:
    9522094
  • 财政年份:
    2016
  • 资助金额:
    $ 72.79万
  • 项目类别:
Dopamine-2 Receptor Partial Agonist for Bipolar Disorder and Alcohol Use Disorder
多巴胺 2 受体部分激动剂治疗双相情感障碍和酒精使用障碍
  • 批准号:
    9175896
  • 财政年份:
    2016
  • 资助金额:
    $ 72.79万
  • 项目类别:
Dopamine-2 Receptor Partial Agonist for Bipolar Disorder and Alcohol Use Disorder
多巴胺 2 受体部分激动剂治疗双相情感障碍和酒精使用障碍
  • 批准号:
    9352266
  • 财政年份:
    2016
  • 资助金额:
    $ 72.79万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了